MRI foundation models (FMs) have shown potential for improving performance of neuroimaging tasks, but their value specifically in Glioblastoma overall survival risk prediction remains unclear. In this study, we explored foundation model initialization for preoperative risk prediction using publicly available structural MRIs from 1007 patients across three glioblastoma cohorts: UPENN-GBM, UCSF-PDGM and TCGA-GBM. The primary analysis finetuned a Swin vision transformer, initialized with BrainSegFounder weights, and compared performance to matched random initialization, and a radiomics baseline. We additionally evaluated recently released FMs, including BrainMVP, BrainIAC, and TRIAD, within the same adaptation strategy, and explored multimodal integration of diffusion tensor imaging-based risk predictions, age, extent of surgical resection, and MGMT methylation status into predictions. In 10-fold UPENN-GBM cross-validation, BrainSegFounder improved mean C-index compared to matched training from scratch and radiomics (0.667 ± 0.053 vs 0.649 ± 0.040 and 0.612 ± 0.044) and achieved time-dependent AUROCs between 0.766 ± 0.089 and 0.799 ± 0.073 across survival horizons under one year. All tested FMs improved over matched random initialization. Within complete-case subsets, multimodal integration improved performance (C-Index 0.691 ± 0.053). Leave-one-cohort-out validation showed performance in external settings consistent with the broader GBM survival prediction literature. These findings suggest incremental value of FM initialization for GBM risk stratification and supports continued benchmarking, adaptation, and validation.
The CAF-derived risk score offers prognostic information complementary to routine clinical variables, representing a promising noninvasive tool for individualized risk stratification when molecular profiling is incomplete or unavailable; these findings warrant prospective external validation before clinical use.
Shi-Chao Liu, Risheng Liang· Frontiers in Oncology· 0 citations
Abstract Foundation models for neuro-oncology have shown promise for non-invasive molecular characterization and prognostication, yet their clinical utility remains limited by cross-institutional distribution shift and poor performance on under-represented molecular alterations. We developed NeuroRAD-FM, combining self...
Moinak Bhattacharya, Annie Singh, Angelica P. Kurtz et al.· Research Square· 0 citations
Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with a median overall survival of 15 months. Longitudinal, multi-modal imaging datasets with comprehensive clinical and treatment data are essential to support the development of reproducible computational methods for treatment response prediction...
Alexandre G. Leclerq, Noémie N. Moreau, H. Audebert et al.· Machine Learning for Biomedi...· 0 citations
A representative clinical scenario involves a 57-year-old patient whose brain MRI reveals an infiltrative mass with central necrosis, with biopsy confirming glioblastoma (GBM, WHO Grade 4). Despite maximal resection, concurrent temozolomide, and radiotherapy, median survival remains 14–16 months, a figure that has rema...
Ayoade Iyiade Victor· Asian Journal of Computer Sc...· 0 citations
Precise prediction of tumor progression between successive post treatment MRI scans could support timely clinical decision making in glioma management. However longitudinal radiomic modeling is still challenged by patient level data leakage and uncertainty in prediction. The study of two stage machine learning pipeline...
A. Rai· Journal of Intelligent Decis...· 0 citations
Accurate prediction of tumor recurrence in brain tumor patients following surgery is essential for optimizing adjuvant therapy, response assessment, and surveillance regimen. While MRI remains the gold standard for surveillance, integrating patient-specific clinical context may inform recurrence prediction. Traditional...
D. Tak, D. Sreedhar, H. Aerts et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.